A daily tablet called solengepras has shown promise in easing the ‘off’ periods that plague people with Parkinson’s, cutting the time patients spend feeling stiff or shaky by nearly half an hour each day, according to a large international trial. The findings suggest the medication could become a new option for patients within three years.
How Solengepras Works
Unlike the existing dopamine‑boosting medicines, solengepras blocks the GPR6 receptor, a pathway that normally dampens movement. By inhibiting this signal, the drug aims to smooth out motor fluctuations without the nausea, hallucinations or involuntary twitches that often accompany current treatments.
Trial Details and Outcomes
The randomised, double‑blind, placebo‑controlled trial enrolled 341 participants with Parkinson’s disease across the United States, Europe, the United Kingdom and Australia. Each volunteer took either a 75 mg dose, a 150 mg dose of solengepras, or a placebo once daily for twelve weeks, while continuing their regular dopamine therapy. Those on the higher dose experienced almost 37 minutes less ‘off’ time each day when their dopamine medication was ineffective, and roughly ninety minutes less overall compared with baseline. They also gained about an hour and a half of ‘on’ time free from dyskinesia, making everyday tasks such as dressing or cooking easier. Improvements were seen across several measures, including daytime alertness and quality of life, and the higher‑dose group reported around thirty‑six extra minutes of functional movement without involuntary shaking.
Safety and Future Outlook
The medication was well tolerated, with no serious adverse events; the most common complaints were mild headaches and urinary tract infections. Cerevance plans to present these findings to the U.S. Food and Drug Administration and aims to have the pill available within three years if regulatory approval follows.
Why it Matters
For the 166,000 people in the UK living with Parkinson’s — and the many more worldwide — this breakthrough could transform daily life, offering longer periods of independence and reduced reliance on medicines that cause troubling side effects. If the drug reaches the market within the next few years, it may set a new standard for managing motor fluctuations, a notoriously difficult aspect of the disease, and inspire further research into non‑dopaminergic therapies.
